Office of the Assistant Secretary for Health

A New Frontier in Cancer Treatment: Azra AI Partners with CancerX to Harness the Power of AI

Retrieved on: 
星期二, 十一月 7, 2023
Medical Devices, Health, Technology, Artificial Intelligence, Oncology, Knowledge, Cancer Moonshot, Dime, Intelligence, H. Lee Moffitt Cancer Center & Research Institute, Multi, Assistant, White House, Life, Office of the Assistant Secretary for Health, Office of the National Coordinator for Health Information Technology, Pathology, Conference, Artificial intelligence, Radiology, Caregiver, Water, Health equity, Partnership, Cancer, Machine learning, Health care, Hospital, Association of British HealthTech Industries, White House Initiative on Asian Americans, Native Hawaiians, and Pacific Islanders, Azra, ONC, Patient, Navigation, Medical device, Pharmaceutical industry, Medical imaging, AI

CancerX was announced by U.S. President Joe Biden and Dr. Jill Biden in February 2023 as part of the White House's reignited national Cancer Moonshot .

Key Points: 
  • CancerX was announced by U.S. President Joe Biden and Dr. Jill Biden in February 2023 as part of the White House's reignited national Cancer Moonshot .
  • CancerX is a collaboration of leaders in the oncology and digital health space to set priorities and practices that will help harness the full power of innovation to achieve the goals of the Cancer Moonshot.
  • "Multi-stakeholder collaboration is critical to harness the potential of digital innovation in the fight against cancer, and we're honored to partner with Azra AI to achieve the ambitious goals of CancerX," said Smit Patel, associate program director, DiMe.
  • "At Azra AI, we’re profoundly inspired to join forces with CancerX, united in our commitment to accelerate groundbreaking cancer innovation.

Leidos to Lead Climate Sustainability and Resilience Strategies for the Department of Defense

Retrieved on: 
星期四, 十月 19, 2023
Science, NYSE, United States Department of Defense, Assistant, Operation, RMI, EI, U.S. Department of Defense Strategy for Operating in Cyberspace, BPA, LDOS, Office of the Assistant Secretary for Health, Carbon accounting, Senior, ICF, RMI (energy organization), Education for librarianship, GHG, McKinsey & Company, Government, Management, Industrial design, Environment, Leidos, Defense

Under the SCSRS contract, Leidos will bring together experts in climate science, mitigation and adaptation to integrate climate resilience into the DoD's core functions to preserve and enhance mission performance.

Key Points: 
  • Under the SCSRS contract, Leidos will bring together experts in climate science, mitigation and adaptation to integrate climate resilience into the DoD's core functions to preserve and enhance mission performance.
  • The work will focus on Department climate, sustainability and resilience initiatives with science, data, and innovation.
  • Additionally, it will focus on shaping effective communication strategies and facilitating organizational change to align with the imperatives of climate sustainability.
  • This award follows Leidos' Climate Data Analytics Framework (CDAF), a multi-year and multi-million dollar technology investment, which encompasses solutions for climate data storage, cataloging, stewardship, processing, analysis, visualization, delivery, and reporting.

Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million

Retrieved on: 
星期三, 九月 27, 2023
Vaccine, United States Department of Health and Human Services, Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Health, Nextgen, Therapy, Office of Inspector General, U.S. Department of Health and Human Services, HHS, Fred Hutchinson Cancer Research Center, SARS-CoV-2, Human services, Gritstone bio, COVID-19, Infection, Federal, Messenger, Assistant, Government, Development, Trust, Controversies regarding COVID-19 contracts in the United Kingdom, NIAID, CORAL, BARDA, Safety, Pharmaceutical industry, Gritstone

EMERYVILLE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that it was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to conduct a Phase 2b comparative study evaluating Gritstone’s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus other viral targets to protect against COVID-19. The agreement, which is valued at up to $433 million, was awarded as part of ‘Project NextGen,’ an initiative by the U.S. Department of Health and Human Services (HHS) to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection for COVID-19.

Key Points: 
  • Under the contract, Gritstone bio will conduct a 10,000 participant, randomized Phase 2b double-blinded study to compare the efficacy, safety, and immunogenicity of the Gritstone next-generation COVID-19 vaccine candidate with an approved COVID-19 vaccine.
  • Preparations for the study are underway, and execution of the study will be fully funded by BARDA.
  • CORAL was designed to address these limitations by inducing durable neutralizing antibody and T cell-based immunity against current and future SARS-CoV-2 variants.
  • We are excited about this opportunity to work alongside BARDA and look forward to initiating the Phase 2b study (CORAL-BARDA) in the first quarter of 2024.

College Athletes Experience Worse Post-Injury Outcomes for Concussions Suffered Outside of Sports

Retrieved on: 
星期三, 九月 20, 2023
Online, Concussion, NCAA, Male, Tactical Combat Casualty Care, DSM-IV codes, Consortium, CHOP, Traumatic brain injury, Stroke, Quality of life, Mind, National Collegiate Athletic Association, Falls, Doctor of Philosophy, Bangladesh Technical Education Board, Assistant, Non-sports trading card, Athlete, DOD, CARE, MD, Patient, Department of Defense Serum Repository, Sport, Knowledge, Hospital, Office of the Assistant Secretary for Health, Assistant Secretary of Defense for Health Affairs, Joint Program in Survey Methodology, National Institute of Neurological Disorders and Stroke, Female, Injury, Children's Hospital of Philadelphia, Nursing, Defense, Research, Education

PHILADELPHIA, Sept. 20, 2023 /PRNewswire/ -- Researchers from Children's Hospital of Philadelphia (CHOP) found that college athletes had worse post-injury outcomes related to concussions they experienced outside of sports than those they experienced while playing sports. Additionally, female athletes who sustained their injury outside of sports had more severe symptoms and more days in sports lost to injury relative to male athletes. These findings suggest the need for improved concussion recognition, reporting, and monitoring outside of sports.

Key Points: 
  • PHILADELPHIA, Sept. 20, 2023 /PRNewswire/ -- Researchers from Children's Hospital of Philadelphia (CHOP) found that college athletes had worse post-injury outcomes related to concussions they experienced outside of sports than those they experienced while playing sports.
  • Additionally, female athletes who sustained their injury outside of sports had more severe symptoms and more days in sports lost to injury relative to male athletes.
  • Concussions have the potential to impact the daily function and quality of life of those who sustain them.
  • Some research has indicated that patients with non-sports-related concussions have worse outcomes, but research into those effects in college-age patients is very limited.

Phoenix PharmaLabs’ Lead Compound, PPL-138, Offers Promise as PTSD/AUD Treatment

Retrieved on: 
星期四, 九月 14, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Florida Atlantic University, Fort Detrick, University, University of Oklahoma Health Sciences Center, Use, College of Medicine, Anxiety, Department of Agriculture and Fisheries (Queensland), United States Department of Defense, FAU, Tic disorder, Research, Assistant, Pain, United States Army, Charles E. Schmidt College of Medicine, United States Department of the Army, Animal, Acquisition, Alcohol, Department of Defense Office of Inspector General, NIDA, Biomedical sciences, PASA, FDA, Trauma, Chronic pain, IND, OUHSC, Office of the Assistant Secretary for Health, Assistant Secretary of Defense for Health Affairs, PTSD, Substance abuse, Pharmaceutical industry, Meat, Pharmacy, Defense, Neuroscience, Professor

Dr. Cippitelli has been examining the ability of the drug to reduce alcohol consumption in anxiety-susceptible or anxiety-resistant PTSD subjects.

Key Points: 
  • Dr. Cippitelli has been examining the ability of the drug to reduce alcohol consumption in anxiety-susceptible or anxiety-resistant PTSD subjects.
  • “We chose this model of PTSD because it produces a wide range of comorbidities experienced by those diagnosed with PTSD.
  • A patent application for the Use of PPL-138 for treatment of PTSD/AUD has just been filed.
  • In addition to the company’s lead compound, PPL-138, Phoenix has a portfolio of 25 other compounds that have the potential to treat pain, substance abuse and addiction.

CancerX Announces Steering Committee and Strategic Priorities

Retrieved on: 
星期二, 九月 12, 2023
Learning, White House, Office of the National Coordinator for Health Information Technology, Amazon Web Services, Partnership, Senior, Public policy, Health care, Moonshot, Cancer, MBA, Research, Technology policy, Doctor of Philosophy, Assistant, Government, Cancer Moonshot, Organization, ONC, H. Lee Moffitt Cancer Center & Research Institute, Janssen Pharmaceuticals, Office of Science and Technology Policy, Patient, Machine learning, Chief digital officer, Diagnosis, Johnson & Johnson, Federation, Ecosystem, Health, Chief commercial officer, R, Assistant director, Office of the Assistant Secretary for Health, AWS, Dana, SVP, Dime, Caregiver, Safety, Disease, Dana–Farber Cancer Institute, Pharmaceutical industry, Management, Creative industries, Medical imaging, Science, Yosemite National Park, Accelerator

BOSTON, Sept. 12, 2023 /PRNewswire/ -- CancerX, the public-private partnership that launched in March of this year to harness the power of innovation to help achieve the goals of the Cancer Moonshot, announced its inaugural steering committee and strategic priorities. CancerX is co-hosted by the Digital Medicine Society (DiMe) and Moffitt Cancer Center alongside the Office of the National Coordinator for Health Information Technology (ONC) and the Office of the Assistant Secretary for Health (OASH).

Key Points: 
  • BOSTON, Sept. 12, 2023 /PRNewswire/ -- CancerX, the public-private partnership that launched in March of this year to harness the power of innovation to help achieve the goals of the Cancer Moonshot, announced its inaugural steering committee and strategic priorities.
  • CancerX is unmatched in convening leading innovators from across the country," said Mary Tolikas, PhD, MBA, SVP & Chief Innovation Officer,  Dana-Farber Cancer Institute.
  • Representatives from over 125 CancerX member organizations also joined The White House officials and representatives from across the federal government to set strategic priorities and outline activities for CancerX that align with and augment the broader Cancer Moonshot community.
  • The group set the following strategic priorities for Year 1 of CancerX:
    Demonstrate CancerX as the global leader in advancing digital innovation in oncology in alignment with the goals of the reignited Cancer Moonshot.

Oncology Care Partners Joins CancerX to Amplify the Power of Innovation to Fight Cancer

Retrieved on: 
星期三, 八月 30, 2023
White House, Office of the National Coordinator for Health Information Technology, Partnership, Office of the Assistant Secretary for Health, Life, Cancer, Quality of life, White House Initiative on Asian Americans, Native Hawaiians, and Pacific Islanders, Human, Oracle, Assistant, Cancer Moonshot, ONC, City, OCP, Patient, Physician, Multi, American Cancer Society, H. Lee Moffitt Cancer Center & Research Institute, Health, Dime, Caregiver, Nursing

NASHVILLE, Tenn., Aug. 30, 2023 /PRNewswire/ -- Oncology Care Partners (OCP), an innovative oncology provider built solely to improve the patient experience through value-based care, today announces its partnership with CancerX—a public-private partnership to boost innovation in the fight against cancer.

Key Points: 
  • NASHVILLE, Tenn., Aug. 30, 2023 /PRNewswire/ -- Oncology Care Partners (OCP), an innovative oncology provider built solely to improve the patient experience through value-based care, today announces its partnership with CancerX —a public-private partnership to boost innovation in the fight against cancer.
  • CancerX is a collaboration of leaders in the oncology and digital health space to set priorities and practices that will help harness the full power of innovation to achieve the goals of the Cancer Moonshot.
  • "Multi-stakeholder collaboration is critical to harness the potential of digital innovation in the fight against cancer, and we're honored to partner with Oncology Care Partners to achieve the ambitious goals of CancerX," said Smit Patel, associate program director, DiMe.
  • As the first and only community-based oncology practice to be part of CancerX, OCP advances value-based care in oncology nationwide by providing high-touch, whole-person care that enhances the patient experience across its medical oncology practices.

MediMergent Joins CancerX as a Founding Member, Escalating the Voice of the Patient as an Essential Component in the Fight Against Cancer

Retrieved on: 
星期二, 八月 29, 2023
Real-World Evidence, White House, Office of the National Coordinator for Health Information Technology, Partnership, Life, Big data, Yale Physician Associate Program, Cancer, Research, RWD, Patient, Dime, Assistant, White, Human voice, Algorithm, Cancer Moonshot, RWE, Multi, H. Lee Moffitt Cancer Center & Research Institute, Office of the Assistant Secretary for Health, Real world data, Disease, VOP, Pharmaceutical industry, Health

CancerX is a transformative private-public partnership, initiated by the White House as a part of the renewed Cancer Moonshot program.

Key Points: 
  • CancerX is a transformative private-public partnership, initiated by the White House as a part of the renewed Cancer Moonshot program.
  • Our relationship with CancerX offers us an unparalleled opportunity to propel digital health practices forward, positively impacting all aspects of the cancer patient's experience."
  • Dr. Ken Borow, Chief Medical Officer of MediMergent underscores the pivotal role of the patient's perspective in the fight against cancer.
  • By championing the patient narrative, MediMergent has empowered medical professionals and researchers to gain deeper insights into the unique challenges faced by cancer patients."

PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome

Retrieved on: 
星期二, 八月 1, 2023
Mental Health, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, PRTC, LSE, Defense Health Agency, University of California, Davis, Tremor, Anxiety, University, Therapy, U.S. Department of Defense Strategy for Operating in Cyberspace, United States Department of Defense, Ageing, PureTech Health, FMR1, Research, Medicine, Development director, Element, Veteran, CNS, Dementia, Trial of the century, Science, Assistant, Intellectual disability, FXS, Fragile X syndrome, UC, Patient, Department of Defense Serum Repository, United States Army Medical Research and Development Command, Spectrum, United States Army Medical Research Institute of Infectious Diseases, MIND Institute, FXTAS, Office of the Assistant Secretary for Health, Assistant Secretary of Defense for Health Affairs, Glyph, Cannabidiol, Safety, Allopregnanolone, Pharmaceutical industry, Vaccine, Defense, Fragile

The funds will support a Phase 2 trial of LYT-300 in collaboration with the University of California, Davis (UC Davis).

Key Points: 
  • The funds will support a Phase 2 trial of LYT-300 in collaboration with the University of California, Davis (UC Davis).
  • Both conditions are the result of repeated elements in the Fragile X Messenger Ribonucleoprotein Gene 1 (FMR1) gene.
  • Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.
  • In addition to LYT-300, which is being advanced in three indications, PureTech is progressing multiple CNS-focused programs derived from its Glyph platform.

SOPHiA GENETICS Joins CancerX to Help Accelerate Cancer Research

Retrieved on: 
星期五, 六月 2, 2023
White House, Office of the National Coordinator for Health Information Technology, Business development, Partnership, Office of the Assistant Secretary for Health, Life, Sophia Genetics, Yale Physician Associate Program, Cancer, Intelligence, Research, Assistant, White, ASCO, Cancer Moonshot, Sophia, Incidence, ONC, Data analysis, H. Lee Moffitt Cancer Center & Research Institute, Machine learning, GENETICS, MSK, Memorial Sloan Kettering Cancer Center, Multi, Digital, Dime, Vaccine, Pharmaceutical industry

BOSTON and LAUSANNE, Switzerland, June 2, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced today at ASCO that it has joined as a founding member of CancerX, a new public-private partnership formed to rapidly accelerate the pace of cancer innovation in the United States. As a founding member, SOPHiA GENETICS will help drive the success of CancerX, collaborating to set priorities and practices that will harness the power of innovation to further cancer care and research. SOPHiA GENETICS offers its SOPHiA DDM™ Platform, powered by artificial intelligence and machine learning, to help advance the inaugural project, which looks to improve equity and reduce cost in cancer treatments. 

Key Points: 
  • As a founding member, SOPHiA GENETICS will help drive the success of CancerX, collaborating to set priorities and practices that will harness the power of innovation to further cancer care and research.
  • "As a leader in data-driven medicine, SOPHiA GENETICS is eager to join forces with CancerX and its partners that will lend their expertise towards expediting cancer research and innovation in the U.S.," said Kevin Puylaert, Vice President, Business Development & Marketing for SOPHiA GENETICS.
  • We look forward to leveraging the collective intelligence that our platform creates to help progress cancer research as we embark on our work with CancerX."
  • The SOPHiA DDM™ Platform will not only help bring CancerX partner data together but will accelerate research work to help facilitate breakthroughs.